|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sangamo Therapeutics ( NASDAQ:SGMO ) Third Quarter 2022 Results Key Financial Results Revenue: US$26.5m (down 7.4% from...
Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BRISBANE, Calif., November 03, 2022--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results